Irving, TX, United States
Medisca Inc. recalls
3 recalls recorded since 2018, most recently on 31 March 2025. None are listed as ongoing. Status and classification are as published by the FDA.
Recalls3
Ongoing (FDA)0
Terminated or completed3
Class I (FDA)0
Terminated Class II Drugs
- Recall started
- 31 March 2025
- Terminated
- 10 October 2025
- Reason
- CGMP Deviations
- Distribution
- US Nationwide.
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0386-2025
- Bimatoprost powder, Bulk Ingredient, a) 5g (NDC 38779-3066-03), b) 1g (NDC 38779-3066-06), c) 1g (NDC 38779-3066-09) drums, Medisca, Plattsburgh, NY
Completed Class II Drugs
- Recall started
- 26 June 2024
- Reason
- CGMP Deviations and Presence of Particulate Matter: Glass
- Distribution
- Nationwide in the USA and Canada
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0570-2024
- Budesonide, USP (Micronized), 500 mg, White to off-white odorless, crystalline powder, Medisca Inc., Plattsburgh, NY, 12901, USA, NDC: 38779-3097-00.
Terminated Class II Drugs
- Recall started
- 25 November 2019
- Terminated
- 17 March 2021
- Reason
- Failed Impurities/Degradation Specifications
- Distribution
- Nationwide
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0622-2020
- Estriol, USP (Micronized) 1 g, 5 g, 25 g, 100 g, 2000 g, 1 kg, containers, Packed by Medisca Inc., Plattsburgh, NY 12901, USA
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.